

Sotagliflozin

Catalog No: tcsc1069



Available Sizes

Size: 5mg

Size: 10mg

Size: 25mg

Size: 50mg



Specifications

CAS No:

1018899-04-1

Formula:

$C_{21}H_{25}ClO_5S$

Pathway:

Membrane Transporter/Ion Channel

Target:

SGLT

Purity / Grade:

>98%

Solubility:

10 mM in DMSO

Alternative Names:

LX-4211;LP-802034

Observed Molecular Weight:


424.94

Product Description

Sotagliflozin (LX-4211) is a potent dual SGLT2/1 inhibitor. Antidiabetic agents.

IC50 & Target: SGLT1/2

In Vitro: LX4211 enhanced urinary glucose excretion by inhibiting SGLT2-mediated renal glucose reabsorption; markedly and significantly improved multiple measures of glycemic control, including fasting plasma glucose, oral glucose tolerance, and HbA(1c); and significantly lowered serum triglycerides. LX4211 also mediated trends for lower weight, lower blood pressure, and higher glucagon-like peptide-1 levels. In a follow-up single-dose study in 12 patients with T2DM, LX4211 (300 mg) significantly increased glucagon-like peptide-1 and peptide YY levels relative to pretreatment values, probably by delaying SGLT1-mediated intestinal glucose absorption [1]. LX4211-treated mice and SGLT1-/- mice also had increased GLP-1 AUC values, decreased glucose-dependent insulintropic polypeptide (GIP) AUC values, and decreased blood glucose excursions during the 6 hours after a challenge with oral glucose alone [2].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!